Upgrade to SI Premium - Free Trial

Cowen Reiterates Outperform Rating and $48 PT on Abbott Labs (ABT) Following Q1 Report; 'Expect Sequentially Improving Sales Growth'

April 19, 2017 3:40 PM
Cowen reiterates Outperform rating and $48 price target on Abbott Labs (NYSE: ABT) following the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles